Structures of human M1, M2, and M4 receptors, and rat M3 receptor
| Receptor | PDB ID | Ligand | Efficacy | Fusion Partner | Resolution (Å) | References |
|---|---|---|---|---|---|---|
| M1R | 5CXV | Tiotropium | Inverse agonist | T4 lysozyme (T4L) in ICL3 | 2.70 | Thal et al., 2016 |
| M2R | 3UON | QNB | Inverse agonist | T4L in ICL3 | 3.00 | Haga et al., 2012 |
| M2R | 4MQS | Iperoxo | Full agonist | None | 3.50 | Kruse et al., 2013a |
| M2R | 4MQT | Iperoxo, LY2119620 | Full agonist, PAM | None | 3.70 | Kruse et al., 2013a |
| M2R | 5ZK8 | NMS | Inverse agonist | Cytochrome b562RIL (BRIL) in ICL3 | 3.00 | Suno et al., 2018 |
| M2R (S110R) | 5ZKC | NMS | Inverse agonist | BRIL in ICL3 | 2.30 | Suno et al., 2018 |
| M2R (S110R) | 5ZKB | AF-DX 384 | Antagonist | BRIL in ICL3 | 2.95 | Suno et al., 2018 |
| M2R (S110R) | 5ZK3 | QNB | Inverse agonist | BRIL in ICL3 | 2.60 | Suno et al., 2018 |
| M2R (S110R) | 5YC8 | NMS, Hg | Inverse agonist, cation | BRIL in ICL3 | 2.50 | Suno et al., 2018 |
| M3R | 4DAJ | Tiotropium | Inverse agonist | T4L in ICL3 | 3.40 | Kruse et al., 2012 |
| M3R | 4U14 | Tiotropium | Inverse agonist | Disulfide stabilized T4L in ICL3 | 3.57 | Thorsen et al., 2014 |
| M3R | 4U15 | Tiotropium | Inverse agonist | Minimal T4L (mT4L) in ICL3 | 2.80 | Thorsen et al., 2014 |
| M3R | 4U16 | NMS | Inverse agonist | mT4L in ICL3 | 3.70 | Thorsen et al., 2014 |
| M3R | 5ZHP | Compound 6o (BS46) | Antagonist | mT4L in ICL3 | 3.10 | Liu et al., 2018 |
| M4R | 5DSG | Tiotropium | Inverse agonist | mT4L in ICL3 | 2.60 | Thal et al., 2016 |